Proactive Outreach to Focus on Increasing Awareness and Enhancing Shareholder Value
MIAMI, FL / ACCESSWIRE / August 3, 2016 / Novus Acquisition and Development Corp. (OTC: NDEV), the nation's first healthcare
insurance plan in the medical cannabis field and property and casualty sector, today announced that it has retained Hayden IR, a
fifteen-year old, highly-recognized national investor relations firm. The focus of the engagement is to raise Novus' visibility and
strengthen its relationships with the investment community, increase awareness and enhance shareholder value.
Novus generates and services its members through their automated web portal at: http://www.getnovusnow.com. Over the past year,
Novus insurance programs have diversified from a single oriented line of business, medical cannabis plans, to multiple liability
and specialty lines of business and revenue streams. No one knows Novus' brand in the cannabis space better than their own team,
which is why they have taken control of their digital marketing approach from third party vendors to in-house marketing strategies
resulting to cost-effectively convert and acquire customers.
"Over the past year, our Novus team has successfully taken a vision, implemented a business plan and created an infrastructure
in the rapidly moving legalized cannabis industry. Our company is entering a very exciting phase as legalized medical cannabis
continues to expand state-by-state and now encompasses 24 states. We are excited by our progress to-date as we look to take
advantage of this emerging trend," said Frank Labrozzi, Novus' Chairman and Chief Executive Officer. "We believe it is an
appropriate time to retain a national investor relations firm to help us target and expand our investor audience and ensure we are
communicating effectively with Wall Street. We look forward to working with the team of professionals at Hayden IR to execute this
important goal."
Hayden IR is a premier investor relations consulting firm, connecting undervalued emerging growth companies with institutions,
hedge funds, independent portfolio managers, buy-side and sell-side analysts, retail brokerage firms and accredited individual
investors. Hayden's team of IR professionals draw from "Wall Street," finance, agency and media backgrounds and continuously strive
to maximize the ongoing corporate visibility and market capitalization of clients though a comprehensive, multi-tier proactive
program. Hayden IR always puts its clients in front of investors who can take action immediately, not when the client is larger or
further along the corporate lifecycle. Over time, Hayden IR helps its clients navigate up the Wall Street food chain, broadening
their audience. Hayden IR also consistently adds to its database, from online tools and conferences, as it builds relationships,
one at a time, so there is a history and an understanding of each contact; it's not just a name in the database. The Hayden IR team
brings dozens of years of collective experience and brings a range of expertise to the benefit of its clients.
Stephen Hart, Head of Corporate Advisory at Hayden IR, added, "We are very excited to be working with Novus, a company with a
unique and much-needed product offering in an underserved emerging growth market. Its business model and plans for expansion into
additional insurance lines of business and revenue streams, make Novus well positioned to take advantage of the expected growth of
regulated cannabis over the next few years. The team at Hayden IR looks forward to articulating this opportunity to the
professional investment community."
About Novus
Novus Acquisition & Development Corp. (NDEV), through its subsidiary Novus Medical Group, Inc. and WCIG Insurance, provides
health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal
programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the
MMJ sector.
Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on
the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the
Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The
statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not
intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained
on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your
physician or other health care professional. Once a push notification is competed the transaction is solely between the
state-licensed dispensary and the registered patient.
The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated
that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by
state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current
administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any
such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus
Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a
change in enforcement by federal or state governments.
For more information, check out: http://www.getnovusnow.com.
Forward-Looking Statements
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current
expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results
or events to differ materially from current expectations. Some of these factors include: general global economic conditions;
general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the
expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve
commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy;
changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not
anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims
any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Contact Information
Corporate: Chairman and CEO Frank Labrozzi frank@ndev.biz 855-228-7355
Investors: Hayden IR hart@haydenir.com 917-658-7878
SOURCE: Novus Acquisition and Development Corp.
